%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 15 0 R 18 0 R ] /Count 3 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R /F4 17 0 R >> /ExtGState << /GS1 13 0 R /GS2 14 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260416233929+00'00') /ModDate (D:20260416233929+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 11 0 R ] /Contents 7 0 R >> endobj 7 0 obj << /Length 6114 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Announces the Formation and Members of Scientific)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Advisory Board)] TJ ET BT 35.000 734.017 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 692.827 Td /F1 12.0 Tf [(TORONTO & SAN FRANCISCO??\()] TJ ET 0.000 0.000 0.800 rg BT 232.364 692.827 Td /F1 12.0 Tf [(BUSINESS WIRE)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 232.364 690.217 m 327.716 690.217 l S 0.000 0.000 0.000 rg BT 327.716 692.827 Td /F1 12.0 Tf [(\)??Treadwell Therapeutics, a privately held)] TJ ET BT 35.000 678.175 Td /F1 12.0 Tf [(clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet)] TJ ET BT 35.000 663.523 Td /F1 12.0 Tf [(needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent)] TJ ET BT 35.000 648.871 Td /F1 12.0 Tf [(oncology leaders and drug developers. The SAB will work closely with Treadwell to advance the)] TJ ET BT 35.000 634.219 Td /F1 12.0 Tf [(company??s pipeline of small molecules, biologics and cell therapies.)] TJ ET BT 35.000 607.567 Td /F1 12.0 Tf [(??We are delighted and honored to be working with this prestigious group of innovators and thought)] TJ ET BT 35.000 592.915 Td /F1 12.0 Tf [(leaders as our Scientific Advisory Board. We are very much looking forward to collaborating with this)] TJ ET BT 35.000 578.263 Td /F1 12.0 Tf [(group to inform and shape our research and development efforts in advancing our pipeline,?)] TJ ET BT 530.588 578.263 Td /F1 12.0 Tf [()] TJ ET BT 533.924 578.263 Td /F1 12.0 Tf [( said)] TJ ET BT 35.000 563.611 Td /F1 12.0 Tf [(Roger Sidhu, M.D., Acting CEO of Treadwell. ??This SAB brings tremendous experience in advancing)] TJ ET BT 35.000 548.959 Td /F1 12.0 Tf [(novel therapeutics in oncology from early to late stage development including drug approvals. We are)] TJ ET BT 35.000 534.307 Td /F1 12.0 Tf [(confident that this group will be invaluable in supporting the development of our pipeline with a focus on)] TJ ET BT 35.000 519.655 Td /F1 12.0 Tf [(our lead program CFI-400945, a PLK4 inhibitor currently being advanced in AML.?)] TJ ET BT 479.204 519.655 Td /F1 12.0 Tf [()] TJ ET BT 35.000 493.003 Td /F1 12.0 Tf [(The founding members of the Treadwell Scientific Advisory Board are:)] TJ ET BT 35.000 466.351 Td /F3 12.0 Tf [(Antoni Ribas)] TJ ET BT 109.004 466.351 Td /F1 12.0 Tf [(, M.D., Ph.D., is currently Professor of Medicine, Surgery, and Molecular and Medical)] TJ ET BT 35.000 451.699 Td /F1 12.0 Tf [(Pharmacology at the University of California Los Angeles \(UCLA\), directory of the Tumor Immunology)] TJ ET BT 35.000 437.047 Td /F1 12.0 Tf [(Program at the Jonsson Comprehensive Cancer Center and director of the Parker Institute for Cancer)] TJ ET BT 35.000 422.395 Td /F1 12.0 Tf [(Immunotherapy at UCLA. Dr. Ribas has played a pivotal role in the development and approval)] TJ ET BT 35.000 407.743 Td /F1 12.0 Tf [(pembrolizumab in advanced melanoma and multiple additional drugs in this disease. Dr. Ribas was)] TJ ET BT 35.000 393.091 Td /F1 12.0 Tf [(formerly President of the American Association for Cancer Research and has been elected to the)] TJ ET BT 35.000 378.439 Td /F1 12.0 Tf [(National Academy of Medicine.)] TJ ET BT 35.000 351.787 Td /F3 12.0 Tf [(Carl June)] TJ ET BT 89.684 351.787 Td /F1 12.0 Tf [(, M.D., is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology)] TJ ET BT 35.000 337.135 Td /F1 12.0 Tf [(and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and)] TJ ET BT 35.000 322.483 Td /F1 12.0 Tf [(director of Center for Cellular Immunotherapies at the University of Pennsylvania. Dr. June is)] TJ ET BT 35.000 307.831 Td /F1 12.0 Tf [(internationally recognized for his role in pioneering CAR-T cell therapy which led to the first FDA-)] TJ ET BT 35.000 293.179 Td /F1 12.0 Tf [(approved cellular therapy for children and young adults with acute lymphoblastic leukemia. Dr. June)] TJ ET BT 35.000 278.527 Td /F1 12.0 Tf [(has published more than 500 manuscripts and is the recipient of multiple prestigious scientific)] TJ ET BT 35.000 263.875 Td /F1 12.0 Tf [(achievement awards and is a member of the National Academy of Medicine and the National Academy)] TJ ET BT 35.000 249.223 Td /F1 12.0 Tf [(of Sciences.)] TJ ET BT 35.000 222.571 Td /F3 12.0 Tf [(Pasi A. Jänne)] TJ ET BT 121.700 222.571 Td /F1 12.0 Tf [(, M.D., Ph.D., is a world renowned translational medical oncologist and the Senior Vice)] TJ ET BT 35.000 207.919 Td /F1 12.0 Tf [(President of Translational Medicine at Dana-Farber Cancer Institute and Professor of Medicine at)] TJ ET BT 35.000 193.267 Td /F1 12.0 Tf [(Harvard Medical School. He is the Director of the Belfer Center for Applied Cancer Science. He was a)] TJ ET BT 35.000 178.615 Td /F1 12.0 Tf [(co-discoverer of epidermal growth factor receptor \(EGFR\) mutations that has led to the development of)] TJ ET BT 35.000 163.963 Td /F1 12.0 Tf [(multiple therapeutic strategies for patients with EGFR mutant lung cancer. Dr. Jänne has received the)] TJ ET BT 35.000 149.311 Td /F1 12.0 Tf [(2024 Medal of Honor from the American Cancer Society and multiple awards from ASCO, AACR and)] TJ ET BT 35.000 134.659 Td /F1 12.0 Tf [(ESMO.)] TJ ET BT 35.000 108.007 Td /F3 12.0 Tf [(S. Gail Eckhardt)] TJ ET BT 130.376 108.007 Td /F1 12.0 Tf [(is Associate Dean of Experimental Therapeutics at Baylor College of Medicine and)] TJ ET BT 35.000 93.355 Td /F1 12.0 Tf [(Associate Director of Translational Research at the Dan L Duncan Comprehensive Cancer Center. Dr.)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Annot /Subtype /Link /F 28 /A 12 0 R /Border [0 0 0] /H /I /Rect [ 232.3640 690.4956 327.7160 702.7056 ] >> endobj 12 0 obj << /Type /Action /S /URI /URI (https://www.businesswire.com/news/home/20240213511904/en/Treadwell-Announces-the-Formation-and-Members-of-Scientific-Advisory-Board) >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 14 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 15 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 16 0 R >> endobj 16 0 obj << /Length 7340 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(Eckhardt has served on numerous committees and study sections, including the ASCO Molecular)] TJ ET BT 35.000 805.516 Td /F1 12.0 Tf [(Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee,)] TJ ET BT 35.000 790.864 Td /F1 12.0 Tf [(and the National Cancer Institute \(NCI\) Cancer Centers Study Section. She serves on 10 external)] TJ ET BT 35.000 776.212 Td /F1 12.0 Tf [(advisory boards of NCI-designated cancer centers, is a past member of the Board of Directors of the)] TJ ET BT 35.000 761.560 Td /F1 12.0 Tf [(Association of American Cancer Institutes \(AACI\) and previous Chair of the Cancer Prevention and)] TJ ET BT 35.000 746.908 Td /F1 12.0 Tf [(Research Institute of Texas?? \(CPRIT\) Clinical Trials Advisory Committee. She is a current member of)] TJ ET BT 35.000 732.256 Td /F1 12.0 Tf [(the National Academies of Science, Engineering, and Medicine??s Cancer Policy Forum. Dr. Eckhardt)] TJ ET BT 35.000 717.604 Td /F1 12.0 Tf [(serves on the Board of Directors of Syros Pharmaceuticals and Exelixis and the Scientific Advisory)] TJ ET BT 35.000 702.952 Td /F1 12.0 Tf [(Board of Amgen.)] TJ ET BT 35.000 676.300 Td /F3 12.0 Tf [(Lillian L Siu)] TJ ET BT 102.356 676.300 Td /F1 12.0 Tf [(, M.D., FRCPC, is an internationally recognized expert in the development of novel cancer)] TJ ET BT 35.000 661.648 Td /F1 12.0 Tf [(therapeutics. Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a)] TJ ET BT 35.000 646.996 Td /F1 12.0 Tf [(Professor of Medicine at the University of Toronto. She is the Director of the Phase I Program and Co-)] TJ ET BT 35.000 632.344 Td /F1 12.0 Tf [(Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre,)] TJ ET BT 35.000 617.692 Td /F1 12.0 Tf [(and holds the BMO Chair in Precision Genomics. Dr. Siu served on the Board of Directors for the)] TJ ET BT 35.000 603.040 Td /F1 12.0 Tf [(American Society of Clinical Oncology \(ASCO\) and the American Association for Cancer Research)] TJ ET BT 35.000 588.388 Td /F1 12.0 Tf [(\(AACR\). Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in)] TJ ET BT 35.000 573.736 Td /F1 12.0 Tf [(Oncology Drug Development in 2010. She was awarded the TAT 2020 Honorary Award for)] TJ ET BT 35.000 559.084 Td /F1 12.0 Tf [(contributions in the development of anticancer drugs. In 2023, Dr. Siu is currently the co-Editor-in-Chief)] TJ ET BT 35.000 544.432 Td /F1 12.0 Tf [(for AACR??s newest journal)] TJ ET BT 195.728 544.432 Td /F4 12.0 Tf [(Cancer Research Communications)] TJ ET BT 381.776 544.432 Td /F1 12.0 Tf [(and is on the editorial board for)] TJ ET BT 553.868 544.432 Td /F4 12.0 Tf [(Cell)] TJ ET BT 35.000 529.780 Td /F4 12.0 Tf [(and Cancer Cell)] TJ ET BT 121.028 529.780 Td /F1 12.0 Tf [(.)] TJ ET BT 35.000 503.128 Td /F3 12.0 Tf [(Patricia LoRusso)] TJ ET BT 133.028 503.128 Td /F1 12.0 Tf [(, has been a practicing academic medical oncologist performing clinical/translational)] TJ ET BT 35.000 488.476 Td /F1 12.0 Tf [(research in early phase clinical trials for over 30 years, and is currently the Associate Director of)] TJ ET BT 35.000 473.824 Td /F1 12.0 Tf [(Experimental Therapeutics at the Yale Cancer Center and director of their Early Phase Clinical Trials)] TJ ET BT 35.000 459.172 Td /F1 12.0 Tf [(Program. She has had continuous NIH/NCI peer review funding for over 28 years, as well as numerous)] TJ ET BT 35.000 444.520 Td /F1 12.0 Tf [(other team science grants, including SPORE funding and other funding mechanisms such as Stand Up)] TJ ET BT 35.000 429.868 Td /F1 12.0 Tf [(to Cancer \(Co-Leader: Melanoma Dream Team\), the Department of Defense \(DOD\) and the Komen)] TJ ET BT 35.000 415.216 Td /F1 12.0 Tf [(Foundation \(Co-leader, KG111063:Targeting Stem Cells in Triple-Negative Breast Cancer \(TNBC\) in)] TJ ET BT 35.000 400.564 Td /F1 12.0 Tf [(Different Racial Populations\). In addition to serving in NCI extramural positions, Dr. LoRusso is)] TJ ET BT 35.000 385.912 Td /F1 12.0 Tf [(currently serving a 3-year term as the chair of their New Agents Committee \(NAC\), committees for the)] TJ ET BT 35.000 371.260 Td /F1 12.0 Tf [(Cancer Research United Kingdom \(CRUK\). Dr. LoRusso has also served in leadership positions of)] TJ ET BT 35.000 356.608 Td /F1 12.0 Tf [(several other organizations, including the Board of Directors and current President-elect of the AACR,)] TJ ET BT 35.000 341.956 Td /F1 12.0 Tf [(and education and scientific committees of the ASCO. Internationally, she has taught several clinical)] TJ ET BT 35.000 327.304 Td /F1 12.0 Tf [(trials educational workshops, educating many physicians and scientists across the globe. Working)] TJ ET BT 35.000 312.652 Td /F1 12.0 Tf [(closely over the past 3 decades with patients suffering from advanced malignancies, Dr. LoRusso has)] TJ ET BT 35.000 298.000 Td /F1 12.0 Tf [(become an advocate, not only for cancer researchers and clinicians, but more importantly for the)] TJ ET BT 35.000 283.348 Td /F1 12.0 Tf [(patients and their caregivers.)] TJ ET BT 35.000 256.696 Td /F3 12.0 Tf [(Tak Wah Mak)] TJ ET BT 111.020 256.696 Td /F1 12.0 Tf [(, Ph.D., co-founder of Treadwell Therapeutics, is one of the world??s most cited and)] TJ ET BT 35.000 242.044 Td /F1 12.0 Tf [(accomplished scientists. Dr. Mak is currently a Senior Scientist at Princess Margaret Cancer Centre,)] TJ ET BT 35.000 227.392 Td /F1 12.0 Tf [(Director of the Campbell Family Institute for Breast Cancer Research and Professor, Department of)] TJ ET BT 35.000 212.740 Td /F1 12.0 Tf [(Medical Biophysics at the University of Toronto. Dr. Mak is credited with the discovery of the T-cell)] TJ ET BT 35.000 198.088 Td /F1 12.0 Tf [(receptor and pioneering work in the genetics of immunology, including publishing a landmark paper on)] TJ ET BT 35.000 183.436 Td /F1 12.0 Tf [(the discovery and function of the immune checkpoint protein CTLA-4. Dr. Mak is also the founder of)] TJ ET BT 35.000 168.784 Td /F1 12.0 Tf [(Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute)] TJ ET BT 35.000 154.132 Td /F1 12.0 Tf [(myelogenous leukemia in 2017. Dr. Mak has served as author on over 1000 peer-reviewed articles. Dr.)] TJ ET BT 35.000 139.480 Td /F1 12.0 Tf [(Mak is a Fellow of the AACR Academy, has received honorary degrees from many universities around)] TJ ET BT 35.000 124.828 Td /F1 12.0 Tf [(the world and has received various international awards such as the Paul Ehrlich Prize, the Ludwig)] TJ ET BT 35.000 110.176 Td /F1 12.0 Tf [(Darmstaeder Prize and most recently the 2023 International Award for Extraordinary Achievement in)] TJ ET BT 35.000 95.524 Td /F1 12.0 Tf [(Cancer Research from the Pezcoller Foundation and the American Association for Cancer Research)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 17 0 obj << /Type /Font /Subtype /Type1 /Name /F4 /BaseFont /Helvetica-Oblique /Encoding /WinAnsiEncoding >> endobj 18 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 20 0 R 22 0 R ] /Contents 19 0 R >> endobj 19 0 obj << /Length 1838 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(\(AACR\).)] TJ ET BT 35.000 789.484 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 748.294 Td /F1 12.0 Tf [(Treadwell Therapeutics is a clinical-stage oncology company developing novel medicines to address)] TJ ET BT 35.000 733.642 Td /F1 12.0 Tf [(unmet needs in patients with cancer. The Company??s robust, internally developed clinical pipeline)] TJ ET BT 35.000 718.990 Td /F1 12.0 Tf [(includes CFI-400945 \(PLK4 inhibitor\), CFI-402257 \(TTK/Mps1 inhibitor\) and CFI-402411 \(HPK1)] TJ ET BT 35.000 704.338 Td /F1 12.0 Tf [(inhibitor\). Treadwell also has a broad pre-clinical pipeline with multiple biologic and next generation)] TJ ET BT 35.000 689.686 Td /F1 12.0 Tf [(TCR based autologous cell therapy programs. For more information, please visit)] TJ ET 0.000 0.000 0.800 rg BT 463.820 689.686 Td /F1 12.0 Tf [(www.treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 463.820 687.076 m 576.500 687.076 l S 0.000 0.000 0.000 rg BT 576.500 689.686 Td /F1 12.0 Tf [(.)] TJ ET BT 35.000 659.001 Td /F3 14.0 Tf [(Contact)] TJ ET 0.000 0.000 0.800 rg BT 35.000 629.811 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 35.000 627.201 m 137.192 627.201 l S 0.000 0.000 0.000 rg BT 35.000 603.159 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 588.507 Td /F1 12.0 Tf [(February 14, 2024)] TJ ET q 35.000 585.576 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 3)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 20 0 obj << /Type /Annot /Subtype /Link /F 28 /A 21 0 R /Border [0 0 0] /H /I /Rect [ 463.8200 687.3546 576.5000 699.5646 ] >> endobj 21 0 obj << /Type /Action /S /URI /URI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcan01.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.treadwelltx.com%252F%26data%3D04%257C01%257Cm.tusche%2540treadwelltx.com%257C9fada6d2333c422cc9e508da1d9451c2%257C04db3f8aae8b42e388b384cb3a2c34aa%257C0%257C0%257C637854820132066875%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C3000%26sdata%3DwwW9sHtyeKQePfVCHWCu%252F5C56tKDyernS4dxH5H9aVg%253D%26reserved%3D0&esheet=53896205&newsitemid=20240213511904&lan=en-US&anchor=www.treadwelltx.com&index=1&md5=2891f06be7a4ef634c0a07cb63470dbf) >> endobj 22 0 obj << /Type /Annot /Subtype /Link /F 28 /A 23 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 627.4797 137.1920 639.6897 ] >> endobj 23 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj xref 0 24 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000362 00000 n 0000000391 00000 n 0000000540 00000 n 0000000662 00000 n 0000006828 00000 n 0000006935 00000 n 0000007044 00000 n 0000007157 00000 n 0000007291 00000 n 0000007474 00000 n 0000007531 00000 n 0000007588 00000 n 0000007693 00000 n 0000015086 00000 n 0000015202 00000 n 0000015333 00000 n 0000017224 00000 n 0000017358 00000 n 0000018038 00000 n 0000018171 00000 n trailer << /Size 24 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 18248 %%EOF